ASCO: Vorasidenib Improves Progression-Free Survival in Grade 2 IDH-Mutant Glioma
Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.